Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Idec Zevalin

Executive Summary

FDA's Oncologic Drugs Advisory Committee will review Zevalin (ibritumomab tiuxetan) on Sept. 11 for treatment of relapsed or refractory low-grade, follicular, CD20+ transformed, B-cell non-Hodgkin's lymphoma and rituximab-refractory follicular NHL. Meeting will begin at 8 a.m. at the Holiday Inn in Bethesda, Md

You may also be interested in...

Idec Zevalin Phase IV Planned In Murine-Based Cancer Therapy Patients

Idec plans to conduct a Phase IV Zevalin trial to study use of the radioimmunotherapy in patients previously exposed to murine-based anti-cancer therapies, if the product is approved by FDA.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts